SYKHealthcare · Medical DevicesThe 30 Wall Street analysts covering Stryker Corp. hold a median 12-month price target of $334 — -1.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 4 Nov 2026 — in the upper half. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Stryker Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (99): The share price has been relatively steady.
Momentum (38): The shares have been drifting down relative to others.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on SYK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −1.7% from it.
Of the 20 most recent actions, 0 moved their price target up and 15 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Nov 2026 | Stifel | Maintains | Buy | $330 → $325 |
| 2 Nov 2026 | Truist Securities | Reiterates | Hold | $310 → $305 |
| 31 Oct 2026 | JP Morgan | Maintains | Overweight | — |
| 30 Oct 2026 | Barclays | Maintains | Overweight | $375 → $365 |
| 30 Oct 2026 | BTIG | Maintains | Buy | $316 → $304 |
| 30 Oct 2026 | Canaccord Genuity | Downgrade | Hold | $385 → $300 |
| 30 Oct 2026 | Citigroup | Maintains | Buy | $360 → $315 |
| 30 Oct 2026 | Citizens | Maintains | Market Outperform | $400 → $390 |
| 30 Oct 2026 | Evercore ISI Group | Maintains | Outperform | $335 → $320 |
| 30 Oct 2026 | JP Morgan | Maintains | Overweight | $350 → $340 |
| 30 Oct 2026 | Needham | Maintains | Buy | $418 → $359 |
| 30 Oct 2026 | RBC Capital | Maintains | Outperform | $420 → $375 |
| 30 Oct 2026 | TD Cowen | Maintains | Hold | $298 → $290 |
| 12 Oct 2026 | BTIG | Maintains | Buy | $358 → $316 |
| 12 Oct 2026 | BTIG | Maintains | Buy | — |
| 7 Oct 2026 | Barclays | Initiates | Overweight | $375 |
| 7 Oct 2026 | Barclays | Initiates | Overweight | — |
| 7 Oct 2026 | Truist Securities | Maintains | Hold | — |
| 7 Oct 2026 | Truist Securities | Maintains | Hold | $340 → $310 |
| 30 Sept 2026 | Stifel | Maintains | Buy | $360 → $330 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SYK appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Stryker Corp. returned −5.3% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 21% of US stocks
Cheaper than 24% of US stocks
Cheaper than 17% of US stocks
Cheaper than 18% of US stocks
Higher than 47% of US stocks
Higher than 25% of US stocks
Higher than 81% of US stocks
Higher than 82% of US stocks
Higher than 76% of US stocks
Higher than 76% of US stocks
Higher than 89% of US stocks
Higher than 71% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Stryker Corp. has a market value of $129.4B and an enterprise value of $130.4B.
Revenue in the twelve months to 30 June 2026: $25.8B. The latest quarter grew 7.6% year on year.
Net income over the same four quarters: $3.7B, a 14.4% net margin.
Diluted earnings per share, trailing twelve months: $9.65.
Free cash flow in the twelve months to 30 June 2026: $4.7B.
Stryker Corp. spent $1.3B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 36.2×; forward P/E: 20.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 1.04%, paying out 37% of earnings.
Stryker Corp. employs 56,000 people — $461K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Stryker Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Stryker shares fell 11.8% after third-quarter earnings and sales missed estimates. The company cut its 2026 outlook amid weak joint procedures and execution challenges.
Why it matters — The results miss and reduced outlook may be relevant to SYK watchers assessing the company’s performance and near-term business conditions.
Stryker shares fell $26.70, or 8.8%, on September 8, 2026, after the CFO disclosed that a manufacturing issue previously thought resolved was still persisting. The decline erased more than $10 billion in market capitalization.
Why it matters — The disclosure and sharp share-price decline put Stryker’s ongoing manufacturing issue and its market impact in focus for SYK watchers.
Stryker cut its 2026 outlook amid weaker joint replacement demand and supply disruptions, while reporting strength in MedSurg, margin gains and investments in robotics.
Why it matters — The revised outlook and softer demand are relevant to SYK watchers assessing the company’s near-term business conditions.
Stryker reported 7.7% third-quarter organic sales growth and adjusted EPS of $3.52. It lowered its full-year outlook, citing slower hip and knee procedures, ongoing peripheral vascular supply constraints, and capital equipment sales execution risks.
Why it matters — The results and reduced outlook highlight the factors affecting Stryker’s near-term performance.
Stryker posted weaker-than-expected third-quarter results, and analysts cut their forecasts following the earnings report.
Why it matters — SYK watchers may note the analyst forecast reductions after the company’s downbeat quarterly results.
The 30 Wall Street analysts covering Stryker Corp. have a median 12-month price target of $334, with estimates ranging from $275 to $465. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 30 analysts covering Stryker Corp., 23 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Stryker Corp. 73 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Stryker Corp. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).
No one can know that. What the data says: the median 12-month target from 30 analysts implies -1.7% from the last close, and Ticker Nerd's factor model ranks Stryker Corp. 73 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Stryker Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SYK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $275 to $465 over the next 12 months.
Stryker Corp. returned -5.3% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Stryker Corp. is a medical technology company focused on products and services that support patient care and healthcare delivery.
The most recent item we track (Zacks Investment Research, 30 Oct 2026): "SYK Stock Skids as Q3 Earnings and Sales Miss & 2026 Outlook Cut". Stryker shares fell 11.8% after third-quarter earnings and sales missed estimates. The company cut its 2026 outlook amid weak joint procedures and execution challenges.
Stryker Corp. is a medical technology company focused on products and services that support patient care and healthcare delivery. The company operates across MedSurg, Neurotechnology, and Orthopaedics, supplying hospitals, surgeons, and other healthcare providers with surgical equipment, endoscopic and communications systems, patient handling tools, emergency medical equipment, implantable devices, and neurovascular solutions. Its orthopaedics business includes implants used in joint replacement, trauma, and extremities procedures, while its medical and surgical portfolio addresses operating room efficiency, clinical workflows, and perioperative care. Stryker Corp. plays an important role in the global healthcare market by providing technologies that are used in surgery, acute care, and orthopedic treatment across a wide range of clinical settings.
CEO Mr. Kevin A. Lobo · 56,000 employees · United States · https://www.stryker.com
